Private Equity in
Optometry Acquisitions
Who is buying eye care practices, what they require, how their deals are structured, and what clinical life looks like after a PE transaction.
Buyer Intelligence Report — May 2026
The PE Consolidation Thesis in Eye Care
Private equity discovered optometry in the mid-2010s for a simple reason: recurring demand, defensible patient relationships, modest capital requirements per location, and a seller population that is aging out of ownership faster than new independent buyers are stepping in. That thesis has not changed. What has changed is scale.
In 2018, PE-backed platforms operated roughly 900 optometry locations nationally. By 2024, that figure had crossed 3,000 — a 240% increase in six years. The five largest platforms now control 40% of all PE-backed locations. Yet independent practices still represent the majority of the market, which means the acquisition pipeline will remain active for at least a decade.
For selling ODs, understanding who these buyers are — what they look for, how they pay, and what post-close operations actually look like — is as important as knowing your EBITDA multiple. This guide covers all of it. For valuation methodology, see our valuation methods guide. For current multiple benchmarks, see optometry practice multiples 2026.
Active Buyers
The Major PE-Backed Platforms
Acquisitions in optometry fall into two categories: add-ons to existing platforms and new platform formations. More than 80% of all PE transactions are add-ons. The platforms below represent the primary institutional buyers currently acquiring in the US market.
- ▪ 30+ states; active in Southwest
- ▪ Min. revenue: $700K+
- ▪ Single-site and multi-site add-ons
- ▪ Strong optical retail focus
- ▪ Equity rollover: 15–25%
- ▪ Southeast, Mid-Atlantic, expanding West
- ▪ Min. revenue: $600K+
- ▪ Medical optometry preferred
- ▪ Strong managed care contracts
- ▪ Equity rollover: 10–20%
- ▪ National footprint, retail-adjacent
- ▪ Vision plan integration advantage
- ▪ Volume-based practice model
- ▪ Revenue >$800K preferred
- ▪ Rollover: 10–15%
- ▪ State or metro-focused buildouts
- ▪ Min. revenue: $500K–$600K
- ▪ Higher OD involvement post-close
- ▪ Flexibility on structure and terms
- ▪ Rollover: 20–35%; equity upside higher
- ▪ Dry eye, glaucoma, low vision focus
- ▪ Medical billing ratio >40% preferred
- ▪ Higher multiples: 9.0–11.0x EBITDA
- ▪ Ophthalmology cross-referral valued
- ▪ Rollover: 25–40%; active OD equity
- ▪ PE seeking anchor: 5+ locations or $3M+ rev
- ▪ Multiple range: 9.0–12.0x EBITDA
- ▪ Rollover: 30–45%; large equity position
- ▪ OD often stays as clinical director
- ▪ Timeline: 120–180 days to close
Screening Requirements
What PE Platforms Look For
PE platforms filter acquisition candidates through a consistent set of criteria. A practice that clears all thresholds moves to full due diligence. One that misses on two or more factors either passes screening entirely or faces a lower offer.
| Factor | Add-On Minimum | Anchor / Platform | Premium Factors |
|---|---|---|---|
| Annual Revenue | $600K – $800K | $2M – $3.5M+ | Multi-location, growth trend |
| Adjusted EBITDA | $120K – $160K | $400K – $600K+ | Margin >20%, improving trend |
| Payer Mix | <25% Medicaid | <15% Medicaid | High VSP/commercial ratio |
| Geography | Suburban, pop. 50K+ | High-income suburban MSA | Sun Belt, AZ/PHX corridor |
| OD Tenure Plan | 3-year contract | 5-year preferred | Multiple associate ODs |
| Optical Retail | Present, any size | 30%+ of revenue | Specialty lens, premium frames |
| Patient Base | 1,200+ active patients | 3,500+ active patients | Low attrition (<15%/yr) |
| Revenue Growth | Stable (flat–5%) | Growing (5%+/yr) | Organic >8% over 3 years |
Transaction Mechanics
Anatomy of a PE Deal
Most PE acquisitions follow a three-part structure. Each component serves a specific purpose in aligning buyer and seller incentives across a 5–7 year hold period.
70–90% of the total purchase price paid in cash at closing. This is the liquidity event for the selling OD. The cash portion is reduced if a larger equity rollover is negotiated. SBA financing, if used by the acquirer, can affect timing. Larger platforms typically close with institutional capital and move faster.
10–30% of deal value converted into equity in the acquiring platform rather than cash. This is the "second bite of the apple" — if the platform sells five years later at a higher multiple, the rolling OD participates in that upside. Rollover shares are typically locked for 3–5 years. Regional aggregators offer larger rollover positions with more equity upside potential.
Contingent consideration paid over 12–36 months, tied to revenue retention or EBITDA targets. Protects the buyer if patient attrition follows the seller's departure. Earn-out targets are typically 85–95% revenue retention in year one, tightening in year two. Earn-outs that are difficult to achieve are a red flag in any LOI — negotiate hard on the benchmark and measurement method.
The selling OD signs a management agreement — not an employment contract — that defines clinical responsibilities, compensation ($160K–$220K market rate), term (3–5 years), non-compete scope (typically 25–50 mile radius, 2–5 years), and performance expectations. Clinical decisions remain entirely with the licensed OD. Business operations migrate to the platform. Most ODs report this as the most significant post-close adjustment.
Transaction Timeline
The PE Acquisition Process: LOI to Close
PE deals run longer than individual OD acquisitions. Budget 90–150 days from signed LOI to funding. The extended timeline reflects institutional due diligence depth, legal review, and financing coordination — not indecision.
Interactive Tool
PE Buyer Fit Analyzer
Enter your practice profile to see which PE buyer tier would likely pursue you, the expected multiple range, and key positioning factors.
Estimates based on 2026 market benchmarks. Actual PE offers depend on specific financial, operational, and transaction factors. For a transaction-specific analysis, see our practice valuation services.
Market Data
PE Acquisition Activity in Optometry: 2018–2025
Estimated PE and DSO transaction share of total optometry practice sales, by year. Growth has been consistent with a brief pause in 2022–2023 as rising rates compressed deal activity before recovering through 2024–2025.
Decision Framework
PE vs. Individual OD Buyer: Key Differences
Neither path is objectively better. The right buyer depends on your priorities around price, speed, autonomy, and post-close clinical life. This is the comparison most sellers wish they had before signing an LOI.
| Factor | PE / DSO Buyer | Individual OD Buyer |
|---|---|---|
| Purchase Price | 7.0–12.0x EBITDA (30–60% premium) | 4.5–7.0x EBITDA |
| Close Timeline | 90–150 days (due diligence depth) | 60–90 days (SBA financing timeline) |
| Cash at Close | 70–90% (rollover retained) | 85–100% cash at close |
| Clinical Autonomy | Clinical decisions remain OD-driven; business ops centralized | Full clinical and business independence |
| Post-Close Obligation | 3–5 year management agreement required | 1–3 year transition typically; negotiable |
| Earn-Out Risk | Significant; tied to retention targets | Minimal or none |
| Upside Potential | Equity rollover could 2–5x if platform exits well | No ongoing upside post-close |
| OD Retention at 2yr | ~82% remain with platform | Typically departs within transition period |
The decision to sell to PE versus an individual OD is rarely just about price. For ODs with 5–10 years left in practice, the equity rollover and continued income often make PE attractive even accounting for the management agreement. For ODs ready to fully exit, individual buyers with clean SBA deals may offer a simpler and faster path. For a structured comparison of both paths, see our exit strategies guide.
2026 Market Context
PE Activity: By the Numbers
Get Positioned Before the Conversation Starts
Know Your PE Position
PE platforms approach acquisition conversations already knowing your revenue, your location's demographics, and your competition. You should know the same things about them. Lumina advises optometry owners through PE and DSO transactions across Arizona and the Southwest.
Common Questions
Frequently Asked Questions
The largest active PE-backed platforms in optometry include EyeCare Partners (Partners Group, 800+ locations), MyEyeDr / Vision Integrated Partners (Goldman Sachs Asset Management, 900+ locations), Eyeglass World / Visionworks (VSP Global, 700+ locations), and a range of regional aggregators. Most individual acquisitions are add-ons to existing platforms rather than new platform formations. The five largest platforms control roughly 40% of all PE-backed optometry locations nationally.
PE-backed platforms primarily screen on revenue (minimum $600K–$800K), adjusted EBITDA (minimum $120K for add-on candidates, $400K+ for anchor locations), geography (preference for Sun Belt, high-income suburban markets), payer mix (commercial insurance over Medicaid-heavy), and OD stability (preference for OD willing to continue 3–5 years post-acquisition). Multi-location practices command premiums of 1.0–2.5x additional EBITDA multiple compared to single-site.
A typical PE acquisition involves three components: cash at close (70–90% of purchase price), equity rollover (10–30% of deal value converted to equity in the acquiring platform rather than cash), and an earn-out (contingent consideration tied to 12–36 month revenue retention). The selling OD typically signs a 3–5 year management agreement. The equity rollover is designed to align incentives — if the platform later sells at a higher multiple, the rolling OD participates in that upside.
Clinical decisions — diagnosis, treatment protocols, prescribing, and patient care standards — remain entirely with the licensed OD post-acquisition. PE platforms acquire business operations, not the medical practice. Business decisions (scheduling, staffing, optical retail pricing, vendor contracts) typically migrate to the platform. OD retention rates at PE-backed platforms run approximately 82% at the two-year mark, which suggests most sellers find the transition workable, though it is a significant operational shift from independent practice ownership.
PE and DSO buyers pay 7.0–9.5x adjusted EBITDA for single-site add-on acquisitions, and 8.0–12.0x for anchor platform practices with 5+ locations or $3M+ revenue. This is 30–60% more than individual OD buyers pay (4.5–7.0x EBITDA). The premium reflects lower institutional capital costs, synergy extraction, and the strategic value of adding locations to a regional network. Geography, payer mix, and OD tenure all affect the final multiple. See our practice multiples 2026 guide for detailed benchmarks.